Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

First thalidomide clinical trial in multiple myeloma: a decade.

van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B.

Blood. 2008 Aug 15;112(4):1035-8. doi: 10.1182/blood-2008-02-140954. Epub 2008 May 23.

2.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.

Hematol J. 2002;3(4):185-92.

PMID:
12189564
3.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM.

Blood. 2003 Jul 1;102(1):69-77. Epub 2003 Mar 13.

4.

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.

J Clin Oncol. 2009 Aug 1;27(22):3664-70. doi: 10.1200/JCO.2008.21.0948. Epub 2009 May 18.

5.

Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.

Barlogie B Jr, Shaughnessy JD.

Int J Hematol. 2002 Aug;76 Suppl 1:337-9.

PMID:
12430877
6.

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R.

Clin Cancer Res. 2005 Aug 1;11(15):5504-14.

7.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

8.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
9.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.

10.

Antitumor activity of thalidomide in refractory multiple myeloma.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.

N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.

11.

Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.

Iwama K, Chihara D, Tsuda K, Ugai T, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K.

Eur J Haematol. 2013 Feb;90(2):134-41. doi: 10.1111/ejh.12050. Epub 2013 Jan 7.

PMID:
23210517
12.

[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].

Agata M, Sameshima Y, Oda T, Kondo T, Ishiyama M, Yasunami T, Kazama H, Okamura T, Yoshinaga K, Shiseki M, Mori N, Yamada O, Sagawa K, Teramura M, Motoji T.

Rinsho Ketsueki. 2010 Mar;51(3):189-95. Japanese.

PMID:
20379113
13.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J.

N Engl J Med. 2006 Mar 9;354(10):1021-30.

14.

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.

Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M.

Haematologica. 2002 Apr;87(4):408-14.

15.

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.

Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J.

Br J Haematol. 2003 Aug;122(4):607-16.

PMID:
12899716
16.

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A, Petty N, Crowley J.

J Clin Oncol. 2010 Jun 20;28(18):3023-7. doi: 10.1200/JCO.2009.26.4465. Epub 2010 May 17.

17.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
18.

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.

Steurer M, Spizzo G, Mitterer M, Gastl G.

Onkologie. 2004 Apr;27(2):150-4.

PMID:
15138347
19.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G.

Blood. 2001 Jul 15;98(2):492-4.

20.

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E.

Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26.

PMID:
20739955
Items per page

Supplemental Content

Write to the Help Desk